Fig. 8

The treatment of Giripladib combined with clinic therapeutic drugs efficiently eliminates BCSCs. A–D The indicated BCSC or non-BCSC cells were treated with designed tamoxifen (A, C) or doxorubicin (B, D) for 48 h. Cell viabilities were measured by CCK-8 assay. E qRT-PCR analysis of lncROPM and PLA2G16 expressions in BCSCs from breast cancer resistant cells and their parental cells. F, G Representative images of mammospheres (F) and mammosphere-formation efficiencies (G) of BCSCs from MCF7 treated with DMSO, Tamoxifen, Giripladib, Tamoxifen + Giripladib or Hs578T treated with DMSO, Doxorubicin, Giripladib, or Doxorubicin + Giripladib. Original magnification, × 40. Scale bars, 400 μm. H Representative images of xenograft tumors for each group (n = 5). I Xenograft tumors volume. J Representative images of IHC staining of KLF4 in each of xenograft tumor group (magnification, × 200. Scale bar, 100 µm). Data are presented as the mean ± SD; *p < 0.05, **p < 0.01